What is the Impact of Tregs on Cancer Immunotherapy?
The presence of Tregs in the TME poses a significant challenge for cancer immunotherapy. Tregs can inhibit the efficacy of immune checkpoint inhibitors, CAR-T cell therapy, and other therapeutic strategies aimed at boosting the anti-tumor immune response. Therefore, strategies to deplete or inhibit Tregs are being explored to enhance the effectiveness of cancer immunotherapies.
